Vir Biotechnology, Inc. VIR

Updated: 18 Jun 2026

NASDAQ | Biotech | Immunology and infectious disease treatments

No signal published yet

We already track Vir Biotechnology and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Vir Biotechnology free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Immunology and infectious disease treatments
We're already tracking Vir Biotechnology, Inc. — here are the latest events we've registered

Recent News

  • On June 9, 2026, Vir appointed Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee. In May 2026, the company reported positive Phase 2 data for chronic hepatitis delta, with 88% of participants achieving undetectable viral loads. Topline data from the pivotal Phase 3 ECLIPSE 1 trial is expected in the fourth quarter of 2026.

What Firelda Watch includes for Vir Biotechnology, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Vir Biotechnology, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Moderna, Inc.
MRNA
HOLD
AstraZeneca PLC
AZN
HOLD
Calliditas Therapeutics
CALT
NEUTRAL
Ionis Pharmaceuticals, Inc.
IONS
HOLD

Biotech

More companies in this sector

Want to follow Vir Biotechnology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Vir Biotechnology free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Vir Biotechnology, Inc. VIR
Vir Biotechnology — follow and we'll monitor it
Follow Vir Biotechnology free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.